BioSig Tech. (BSGM) & Electrophysiology Sector - Roth-BSGM: BioSense Webster Talent Exodus to BioSig Tech Continues - plus additional information on - BioSig Tech. (BSGM) & Electrophysiology Sector - InvestorVillage
BioSig Tech. (BSGM) & Electrophysiology Sector
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: BioSig Tech. (BSGM) & Electrophysiology Sector   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4 of 300  at  2/20/2019 1:38:28 PM  by

Rob Cos

The following message was updated on 6/2/2019 11:10:25 PM.

Roth-BSGM: BioSense Webster Talent Exodus to BioSig Tech Continues - plus additional information on the JNJ stars leaving their and coming to small BSGM...

   

Roth on JNJ exodus to BSGM-WHY?

Why are these superstars from JNJ moving to small BSGM. Why did their shining star sales and commerical guy just leave for BSGM? World class product being tested this week in humans by number one AFib Ablation doc in the world - thats why.
 

Healthcare: Medical Technology

BioSig Technologies, Inc. | BSGM - $4.43 - NASDAQ | Buy

Company Update

12-Mo.Price Target $14.00  

BSGM: BioSense Webster Talent Exodus to BioSig Tech Continues

This morning, BSGM announced the appointment of MaryAnn Edzards as Senior Director - Account Manager. Mrs. Edwards represents the fourth member of BioSense's leadership team to join BioSig ahead of the PURE EP launch.

The key takeaways, in our opinion, include:
 
1) another BioSense team addition boosts our confidence in the upcoming PURE EP launch, and
 
2) there could be a larger story behind the ongoing talent transfer from BioSense to BioSig. Reiterate Buy rating, $14/share price target.
 

Takeaway #1 - Another apparent EP rock star joins BioSig's leadership team. This morning, BSGM announced the appointment of MaryAnn Edzards as Senior Director - Account Manager. Mrs. Edzards comes to BioSig with over 10 years of experience in electrophysiology (EP), including six years at Biosense Webster (JNJ-NC), where she most recently served as New Technology Education Manager (responsibilities included all internal and external marketing and training programs for two global product launches). Mrs. Edzards has facilitated the training of hundreds of field and in-house employees on how to incorporate complex technologies using both virtual and live classroom environments. Importantly, we believe that she will successfully execute on multiple fronts for BioSig, since she has also held clinical, account management and marketing positions while at BioSense. We believe that Mrs. Edzards is a validated commercial leader in EP, as a former EP nurse and the recipient of numerous Johnson & Johnson awards, including the 2016 Standards of Leadership Award and 2017 Gold Encore Award from Commercial Marketing.

Takeaway #2 - There appears to be a larger story here. Mrs. Edzards represents the fourth JNJ/BioSense leader to join BioSig in 2018, including:

1) Chuck Austin (former CEO of Ethicon),2) Amy Scott (former BioSense VP of Physician Engagement), and 3) Stephanie Jasa (former BioSense Senior Director of Global Training and Education). We continue to believe that this is no coincidence, which could bode well for the upcoming PURE EP domestic launch in 2019

Reiterate Buy rating, $14.00/share price target. We encourage investors to accumulate shares at these levels.

_________________________________________________________________ 
 

Two related PRs…. – the JNJ exodus to little $75 mill mkt cap BSGM continues….

Press Release from announcing John Kowalski who was on our call as BioSig’s new VP sales – continuing the exodus from huge JNJ unit BioSense Webster to small BioSig (see Dec 19 Roth report on that Exodus above). Add another

BioSig Appoints John Kowalski to Lead Commercialization of PURE EP

Download as PDF

February 05, 2019

Electrophysiology Industry Veteran to Lead Sales Strategy for the Company’s Novel Cardiac Signal Acquisition and Processing Technology

Santa Monica, CA, Feb. 05, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has appointed Mr. John Kowalski as Vice President of Sales.

Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company. Most recently, he served as Northeast Area Director, a role, in which he was responsible for leading six high-performing cardiac electrophysiology catheter and equipment market sales teams, consisting of 140 sales and clinical support employees. Mr. Kowalski helped drive $175M of disposables and system sales and has consistently exceeded area sales objectives. Having led U.S. strategic planning teams in his previous roles, Mr. Kowalski brings to BioSig proven track record in identifying key business growth opportunities within the cardiac electrophysiology market.

Mr. Kowalski is a holder of numerous Biosense Webster leadership awards, including a record 18-year Founders Club Award, and several “Area and Region of the Year” awards.

“John impressed us with his outstanding leadership skills and unparalleled knowledge of cardiac electrophysiology industry. Given John’s impressive accomplishments as a sales leader, we are confident that he is very well positioned to lead a targeted market launch and grow our commercial capabilities for our innovative technology,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc.

“I am excited to lead the commercial launch of the PURE EP(tm) signal acquisition and processing system. I believe this innovative technology will enable improved diagnosis and treatment of cardiac arrhythmias and benefit millions of people who suffer from this debilitating illness,” commented Mr. Kowalski.

The Company announced that it received the 510(k) clearance for its PURE EP(tm) System on August 14, 2018. BioSig announced in November and December 2018 that it signed agreements to commence the first commercial use of the system at Texas Cardiac Arrhythmia Institute in Austin, Texas, and Mayo Clinic. BioSig signed a 10-year collaboration agreement with Mayo Clinic in March 2017 and announced a new research agreement focusing on development of additional advanced features and potential new applications of PURE EP(tm) System on November 13, 2018.

 
 

BioSig Appoints Johnson & Johnson Veteran Amy Scott

Former Biosense Webster Director of Strategic Partnerships to drive commercial adoption of PURE EP

Santa Monica, CA, Aug. 20, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has partnered with Mrs. Amy Ansfield Scott in order to assist with nationwide KOL engagement ahead of the commercial launch of PURE EP(tm) System in the U.S.

Mrs. Scott brings to the Company over 30 years of experience in medical devices, including over 20 years in electrophysiology (EP). Most recently, she served as Director of Strategic Partnerships for Biosense Webster (Johnson & Johnson), a role which she was responsible for primarily U.S. engagement of physicians and management of the company’s Scientific Advisory Board. Prior to that role, Mrs. Scott was managing a team responsible for driving customer engagement and education, including development of product demonstration and training sites, management of key accounts and liaison between internal clinical and field clinical trials teams. During her career with Biosense Webster, Mrs. Scott also served as Global Product Director for Atrial Fibrillation, the role in which she developed, executed and managed EP/Afib Centers of Excellence. She brings to BioSig extensive experience in defining customer needs and promoting key account relations and activities.

“An experienced and passionate leader like Amy is an invaluable addition to our team. Her expertise in building successful physician relationships and the depth of her marketing knowledge can significantly benefit our effort to launch and expand our clinical operations following our 510(k) clearance,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc.

__________________________________________________________________________________

Chuck Austin’s (Former corporate VP global supply chain at JNJ and member of JNJ management committee – one of 10 running the company) involvement has only increased over the past year. He is an integral part of BSGM team. They also have his right-hand man, Tate Scott - who was global head of business development at Ethicon/Endo-Surgery, JNJ’s large surgical division. PR from last yr:

Johnson & Johnson Veteran Chuck Austin To Scale Up BioSig Operations

Download as PDF

January 09, 2018

Santa Monica, CA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has partnered with Mr. Charles (Chuck) Austin and JK Advisors in order to scale up operational activities ahead of the commercial launch of PURE EP(tm) System.

Mr. Austin brings to the Company over 25 years of experience in medical devices, pharmaceuticals and consumer products. Most recently, he served as Corporate Vice President, Global Supply Chain at Johnson & Johnson, and was a member of the J&J Management Committee. In this role, he was responsible for over 60,000 associates at 130 sites around the world while overseeing over 500 external manufacturers, over $22BB in direct spend, and supported in excess of $70BB in sales. His leadership positions within Johnson & Johnson included Company Group Chairman for Ethicon Surgical Care and Worldwide President for Ethicon Endo-Surgery.

The appointment of Mr. Austin comes at a crucial time for BioSig, as the Company executes its market entry in the U.S. in 2018.

Mr. Austin currently serves on multiple boards in the medical and consumer spaces and is a Principal in JK Advisors, a San Diego based firm focused on the medical space.

“BioSig has impressed us with a strong value proposition and support of leading centers of excellence in the industry. I’m delighted to join the BioSig team at this important time and contribute my knowledge to take the Company to the next level,” commented Mr. Austin.

“BioSig is excited to be working with an executive leader like Chuck. His 25 plus years of experience working for one of the world's leading healthcare organizations can significantly benefit our effort to launch and expand our business operations,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc. “While we expect Chuck to make his initial impact on manufacturing, logistics, and operations, his experience in successfully deploying new commercial models and driving global growth in the medical device marketplace will create value for all our stakeholders. This is an excellent way to kick off our efforts in 2018, which promises to be a pivotal year for the Company

__________________________________________________ 
 

Johnson & Johnson's Biosense Webster’s MaryAnn Edzards Joins BioSig

Former New Technology Education Manager to Assist with First Installations

 

Santa Monica, CA, Dec. 19, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has appointed Mrs. MaryAnn Edzards as Senior Director - Account Manager.

Mrs. Edzards brings to the Company over 10 years of experience in electrophysiology (EP), including six years at Biosense Webster, a Johnson & Johnson company. Most recently, she served as New Technology Education Manager, a role, in which she was responsible for all internal and external marketing and training programs for two global product launches. Mrs. Edzards facilitated training of over 300 field and in-house employees and delivered impactful training modules for complex technologies through virtual and live classroom environments. She brings to BioSig extensive experience in converting Voice of Customer feedback into commercially valuable solutions. Mrs. Edzards is a holder of numerous Johnson & Johnson awards, including 2016 Standards of Leadership Award and 2017 Gold Encore Award from Commercial Marketing.

“A high-performing and motivated professional like MaryAnn is an invaluable addition to our commercial team. Her expertise in delivering highly impactful education and training of both in-house professionals and physicians will tremendously benefit our efforts during the vital First-in-Human patient data collection phase and subsequent market launch in 2019,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc.

The Company announced that it received the 510(k) clearance for its PURE EP™ System on August 14, 2018. BioSig announced on November 28, 2018 that it begins installations of the first systems at Texas Cardiac Arrhythmia Institute in Austin, Texas, followed by another announcement on December 6, 2018 about enrolling Mayo Clinic as the second center for the First-in-Human studies. BioSig signed a 10-year collaboration agreement with Mayo Clinic in March 2017 and announced a new research agreement focusing on development of additional advanced features and potential new applications of PURE EP™ System on November 13, 2018.

“I’m excited to join the BioSig team as the Company commences first installations of PURE EP™ System in some of the leading medical centers of excellence. There is a pressing need for better technological solutions in the space of arrhythmia treatments, and I look forward to contributing my knowledge and expertise to help the Company bring its novel platform onto the market,” commented Mrs. Edzards.


 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 513
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...